Clinical Trials Logo
  1. Home
  2. Takayasu Arteritis
  3. NCT03550781

Anti-inflammatory Treatment for Inactive Takayasu Arteritis — ATITA  

Takayasu Arteritis Clinical Trial

Official title:
Does Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment？

Clinical Trial Summary

Currently, the traditional disease activity of Takayasu arteritis is mainly based on National Institutes of Health criteria and the inactive cases don't need anti-inflammatory treatment. However, pathologic findings showed that there was still inflammatory activity in the affected vessels, and the follow-up data also found significant lesion progression in some inactive cases. Sixty inactive Takayasu arteritis patients will be recruited to determine whether these individuals are active by screening new inflammatory markers in this study. New inflammatory markers included tumor necrosis factor,interleukin-2,interleukin-6,interleukin-8,interleukin-10,high-sensitivity C-reactive protein, and 18f-FDG positron emission tomograph. According to new inflammatory markers, sixty patients will be divided into two categories: inactive patients (n=20) and active patients (n=40). And then, Forty active patients diagnosed by new inflammatory markers will be randomly assigned to either anti-inflammatory therapy group or control group. The changes of inflammatory activity and lesion progression will be observed during one-year follow up in all 60 patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03550781
Study type Interventional
Source Chinese Academy of Medical Sciences, Fuwai Hospital
Contact Xiongjing Jiang, MD
Phone 86-1088322385
Email jxj103@hotmail.com
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date June 1, 2018
Completion date May 31, 2021
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04564001 - Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis Phase 2
Terminated NCT04882072 - A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Phase 3
Completed NCT03750929 - Aerobic Capacity and Strength Exercise in Takayasu's Arteritis N/A
Recruiting NCT04137614 - Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis N/A
Recruiting NCT02967068 - VCRC Tissue Repository
Recruiting NCT05102448 - Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis Phase 4
Recruiting NCT03893136 - The Registry Study of Takayasu Arteritis in East China
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Completed NCT03096275 - Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis Phase 3
Recruiting NCT04300686 - A Pilot Study in Severe Patients With Takayasu Arteritis. Phase 4
Recruiting NCT04299971 - Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Phase 4
Recruiting NCT03192878 - Infliximab Biosimilar in Takayasu's Arteritis N/A
Active, not recruiting NCT04071691 - PET Imaging of Giant Cell and Takayasu Arteritis
Recruiting NCT05904301 - Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Completed NCT02101333 - Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Phase 3
Active, not recruiting NCT05168475 - Biologics in Refractory Vasculitis Phase 2
Completed NCT03956394 - Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging N/A
Recruiting NCT05151848 - Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis Phase 4
Completed NCT03430388 - Yellow Fever Vaccine in Patients With Rheumatic Diseases N/A
Completed NCT02925351 - Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases Early Phase 1